---

6 Oct 2008 : Column 448W—continued

6 Oct 2008 : Column 449W

6 Oct 2008 : Column 450W

6 Oct 2008 : Column 451W

6 Oct 2008 : Column 452W

Topic	Work programme	Published/ongoing	Date of marketing authorisation( 1)	Referral date( 2)	Date of final NICE guidance	Start of NICE appraisal( 3)
Xolair (omalizumab) for uncontrolled asthma	8	Published	October 2005	April 2003	November 2007	November 2006
Remicade (infliximab) for psoriasis	8	Published	September 2005	April 2003	January 2008	March 2007
Natrecor (nesiritide), Heart failure (acute decompensated)	9	Ongoing	n/a	October 2003	n/a	October 2003
Erbitux (cetuximab), Head and neck cancer	10	Published	n/a	June 2004	June 2008	June 2006
Iressa (gefitinib), lung cancer (non-small cell)	10	Ongoing	n/a	June 2004	n/a	January 2009
Tysabri (natalizumab) for the treatment of multiple sclerosis	10	Published	June 2006	June 2004	August 2007	September 2006
Alimta (pemetrexed) for mesothelioma	10	Published	September 2004	June 2004	January 2008	April 2005
Erbitux (cetuximab) for head and neck cancer	10	Published	March 2006	June 2004	June 2008	June 2006
Campto (irinotecan), colon cancer (adjuvant)	10	Ongoing	n/a	June 2004	n/a	n/a
Mabthera (rituximab) for untreated stage III or IV follicular lymphoma	11	Published	August 2004	April 2005	September 2006	April 2007
Taxol (paclitaxel) for early node-positive breast cancer	11	Published	March 2005	April 2005	September 2006	November 2005
Taxotere (docetaxel) for early node-positive breast cancer	11	Published	March 2006	April 2005	September 2006	November 2005
Gemzar (gemcitabine) for metastatic breast cancer	11	Published	September 2004	April 2005	January 2007	February 2006
Fludara (fludarabine) for chronic lymphocytic leukaemia	11	Published	February 2003	April 2005	February 2007	February 2006
Alimta (pemetrexed) for the treatment of non-small cell lung cancer	11	Published	n/a	April 2005	August 2007	April 2006
Tarceva (erlotinib), lung cancer (non-small cell)	11	Ongoing	September 2005	April 2005	n/a	March 2009
Idraparinux sodium, atrial fibrillation	12	Ongoing	n/a	July 2006	n/a	July 2006
Arava (leflunomide), psoriatic arthritis (moderate to severe)	12	Ongoing	June 2004	July 2006	n/a	July 2006
Idraparinux sodium, venous thromboembolism (recurrent)	12	Ongoing	n/a	July 2006	n/a	July 2006
Herceptin (trastuzumab) for early-stage HER2-positive breast cancer	12	Published	May 2006	July 2005	August 2006	December 2005
Alteplase (Actilyse) for the treatment of acute ischaemic stroke	12	Published	June 2002	July 2006	June 2007	September 2006
Champix (varenicline) for smoking cessation	12	Published	September 2006	July 2006	July 2007	November 2006
Humira (adalimumab) for the treatment of psoriatic arthritis	12	Published	August 2005	July 2005	August 2007	September 2006
MabThera (rituximab) for the treatment of rheumatoid arthritis	12	Published	July 2006	July 2005	August 2007	September 2006
Velcade (bortezomib) for multiple myeloma	12	Published	April 2004	July 2005	October 2007	December 2005
Orencia (abatacept) for rheumatoid arthritis	12	Published	May 2007	July 2006	April 2008	October 2006
Tyverb (lapatinib), breast cancer (advanced or metastatic)	13	Ongoing	June 2008	December 2006	n/a	February 2007
Cimzia (certolizumab), rheumatoid arthritis	13	Ongoing	n/a	December 2006	n/a	December 2006
Remicade (infliximab), ulcerative colitis (acute exacerbations)	13	Ongoing	February 2006	December 2006	n/a	March 2007
Remicade (infliximab) for ulcerative colitis	13	Published	February 2006	December 2006	April 2008	March 2007
Acomplia (rimonabant) for obesity	13	Published	June 2006	December 2006	June 2008	June 2007
Baraclude (entecavir), Hepatitis B	14	Ongoing	June 2006	June 2007	August 2008	September 2007
Sebivo (telbivudine), Hepatitis B	14	Ongoing	April 2007	June 2007	August 2008	September 2007
Adenuric (febuxostat), hyperuricaemia	14	Ongoing	April 2008	June 2007	n/a	August 2007
Humira (adalimumab) for the chronic psoriasis	14	Published	December 2007	June 2007	June 2008	July 2007
Ixabepilone, breast cancer (locally advanced or metastatic)	15	Ongoing	n/a	December 2007	n/a	July 2008
Erbitux (cetuximab), colorectal cancer (first line)	15	Ongoing	July 2008	December 2007	n/a	January 2008
Erbitux (cetuximab), lung cancer (non-small cell)	15	Ongoing	n/a	December 2007	n/a	October 2008
Revlimid (lenalidomide), multiple myeloma	15	Ongoing	June 2007	December 2007	n/a	April 2008
Xeloda (capectitabine), pancreatic cancer	15	Ongoing	n/a	December 2007	n/a	June 2009
Pradaxa (dabigatran), venous thromboembolism	15	Ongoing	March 2008	December 2007	n/a	January 2008
Erbitux (cetuximab), head and neck cancer (squamous cell carcinoma)	16	Ongoing	March 2006	March 2008	n/a	March 2008
Effient (prasugrel), acute coronary artery syndrome	17	Ongoing	n/a	June 2008	n/a	November 2008
Viread (tenofovir disoproxil fumarate), Hepatitis B	17	Ongoing	April 2008	June 2008	n/a	August 2008
Nexavar (sorafenib), hepatocellular carcinoma (advanced and metastatic)	17	Ongoing	October 2007	June 2008	n/a	August 2008
Orencia (abatacept), juvenile idiopathic arthritis	17	Ongoing	May 2007	June 2008	n/a	January 2009
Humira (adalimumab), juvenile idiopathic arthritis	17	Ongoing	n/a	June 2008	n/a	September 2008
Sprycel (dasatinib), leukaemia (acute lymphoblastic)	17	Ongoing	November 2006	June 2008	n/a	July 2008
Temodal (temoazolomide), melanoma (advanced and metastatic	17	Ongoing	June 2005	June 2008	n/a	March 2009
Mifamurtide, Osteosarcoma	17	Ongoing	n/a	June 2008	n/a	August 2008
Romiplostim, thrombocytompenic pupura	17	Ongoing	n/a	June 2008	n/a	August 2008
Promacta (eltrombopag), thrombocytopenic purpura	17	Ongoing	n/a	June 2008	n/a	March 2009
Xarelto (rivaroxaban), venous thromboembolism	17	Ongoing	n/a	June 2008	n/a	August 2008
Azacitidine, acute myelomonocytic leukaemia and acute myeloid leukaemia	18	Ongoing	n/a	July 2008	n/a	January 2009
Xeloda (capecitabine), advanced gastric cancer	18	Ongoing	January 2008	July 2008	n/a	December 2008
Methylnaltrexone, opioid-induced constipation in patients receiving palliative care	18	Ongoing	n/a	July 2008	n/a	February 2009
Datiros (alitretinoin), severe chronic hand eczema	18	Ongoing	n/a	July 2008	n/a	October 2008
Alimta (pemetrexed), locally advanced or metastatic non-small cell lung cancer	18	Ongoing	April 2008	July 2008	n/a	June 2009
Mabthera (rituximab), relapsed treatment of chronic lymphocytic leukaemia	18	Ongoing	n/a	July 2008	n/a	September 2009
Mabthera (rituximab), chronic lymphocytic leukaemia.	18	Ongoing	n/a	July 2008	n/a	September 2008
Sutent (sunitinib), gastrointestinal stromal tumours	18	Ongoing	July 2006	July 2008	n/a	August 2008
Actemra (tocilizumab), rheumatoid arthritis	18	Ongoing	n/a	July 2008	n/a	November 2008
Hycamtin (topotecan), carcinoma of the cervix	18	Ongoing	n/a	July 2008	n/a	December 2008
Yondelis (trabectedin), advanced metastatic soft tissue sarcoma	18	Ongoing	September 2007	July 2008	n/a	September 2008
Ustekinumab, moderate to severe psoriasis	18	Ongoing	n/a	July 2008	n/a	November 2008
(1) Date of marketing authorisation by European Medicines Agency (EMEA). (2) Topics before the 13 work programme were originally referred to NICE’s Multiple Technology Appraisal (MTA) programme and were transferred to the STA programme when it was introduced in August 2006. The date provided is the date the topic was originally referred to NICE as a Multiple Technology Appraisal. (3) The date NICE commenced work on the appraisal. NICE will also have carried out scoping work for the appraisal before this date.

---